A standardised test that can detect antibodies against the cells that line the inside of blood vessels
AbSorber has received patent protection for its transplantation cross match-test XM-One in the European countries. Reportedly, the patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product.
The patent was granted by the European Patent Office (EPO) and AbSorber has also patent applications pending for XM-One in the US, Japan and other key transplantation markets. The company expects more countries to follow the European approval of the XM-One patent.
XM-One is the standardised test that can detect antibodies against the cells that line the inside of blood vessels. These endothelial cells are the first point of contact between the transplanted organ and the recipient’s immune system. Anti-endothelial cell antibodies have been shown to play a key role in causing post-transplantation rejections.